Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rechallenge therapy shows promise for Tough-to-Treat colorectal cancer

NCT ID NCT07381764

Not yet recruiting Disease control Sponsor: Gruppo Oncologico Italia Meridionale Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial compares a rechallenge treatment (irinotecan plus cetuximab) against the current standard (trifluridine/tipiracil plus bevacizumab) for people with metastatic colorectal cancer whose disease has worsened after earlier therapies. Only patients with specific genetic markers, identified through a blood test, are eligible. The goal is to see if the rechallenge leads to more tumor shrinkage and better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
irinotecan plus cetuximab
What this could lead to
If successful, this rechallenge approach could offer a more effective third-line treatment option for certain patients with metastatic colorectal cancer.
What could go wrong
This is a phase 2 trial with only 150 participants, so results may not apply broadly. The rechallenge strategy may not work for everyone and could cause side effects like infusion reactions or severe diarrhea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (CRC)

Contacts and locations

Locations

  • A.O. 'Pia Fondazione Cardinale G. Panico'

    Tricase, Italy

  • A.O.R.N. "Sant'anna e San Sebastiano"

    Caserta, Italy

  • A.O.U. Careggi

    Florence, Italy

  • A.O.U. Ospedali Riuniti

    Ancona, Italy

  • A.O.U. Pisana

    Pisa, Italy

  • A.O.U. Sassari

    Sassari, Italy

  • A.O.U. dell'Università degli studi della Campania "Luigi Vanvitelli"

    Naples, Italy

  • A.R.N.A.S. Garibaldi - P.O. Garibaldi-Nesima

    Catania, Italy

  • AOU Policlinico di Modena

    Modena, Italy

  • ARNAS Civico - Di Cristina-Benfratelli - P. O. 'Civico e Benfratelli'

    Palermo, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy

  • ASST Sette Laghi-Ospedale di Circolo Fondazione Macchi

    Varese, Italy

  • Azienda Ospedaliero Universitaria "SS Antonio e Biagio e Cesare Arrigo"

    Alessandria, Italy

  • Azienda Ospedaliero-Universitaria Renato Dulbecco

    Catanzaro, Italy

  • Casa di Cura Villa Maria

    Mirabella Eclano, Italy

  • Casa di cura Macchiarella

    Palermo, Italy

  • Centro di Riferimento Oncologico (CRO), IRCCS

    Aviano, Italy

  • Fondazione IRCCS Istituto Nazionale Tumori

    Milan, Italy

  • Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza

    San Giovanni Rotondo, Italy

  • Fondazione Policlinico Universitario 'Agostino Gemelli' IRCCS

    Roma, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Istituto Nazionale Tumori 'Fondazione G. Pascale'

    Naples, Italy

  • Istituto Oncologico Veneto IRCCS

    Padova, Italy

  • Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'

    Meldola, Italy

  • Ospedale IRCCS 'Saverio de Bellis'

    Castellana Grotte, Italy

  • Ospedale San Giuseppe Moscati

    Statte, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.